Trials / Completed
CompletedNCT01963897
Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of Life.
Duchenne Muscular Dystrophy in Norway. Genotype/Phenotype in Patients Younger Than 18 Years, With a Main Focus on Growth, Puberty, Bone Health and Quality of Life.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 73 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will give a consent based epidemiological overview of Norwegian patients with Duchenne muscular dystrophy younger than 18 years of age. Genotype of the population will be described. Longitudinal development of growth, bone health, and , when applicable, puberty over a two year period will be studied. Questionnaires regarding quality of life will also be an important part of the study.
Detailed description
The participants who are not regularly seen at our regional hospital, are recruited via their local neuropediatrician. Patients who do not come to our region hospital will be seen at their local hospital.Each participant will be seen up to three times with one year between each visit. The visits include clinical examination, DXA scan, x-ray for bone age, and blood tests including several parameters related to bone health, growth and puberty. Standardized questionnaires regarding quality of life (patients and parents) will be used, and certain questions regarding the importance of achieving normal height and puberty will be added. Additional anamnestic data will be retrieved from the patients' medical records.
Conditions
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2013-10-16
- Last updated
- 2017-09-25
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT01963897. Inclusion in this directory is not an endorsement.